Novagali launches dry eye treatment Cationorm

Article

Cationorm, a cationic emulsion to treat dry eye, has been launched in France by Novagali Pharma.

Cationorm, a cationic emulsion to treat dry eye, has been launched in France by Novagali Pharma.

The emulsion, which uses Novasorb technology, acts on the different levels of the tear film. Novasorb, a proprietary platform of Novagali's, uses the electrostatic attraction between the positively charged emulsion and the negatively charged cells of the ocular surface, including cornea and conjunctiva.

Cationorm combines lubricating and hydrating properties to replenish the tear film lipid layer and prevent tear evaporation. Clinical studies have proven the efficacy of Cationorm in treating dry eye symptoms, and it is associated with increased tolerance and comfort.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Andreas Pollreisz, MD, discusses widefield OCT-A and fluorescence angiography at the 2025 European Society of Retina Specialists EURETINA meeting
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
© 2025 MJH Life Sciences

All rights reserved.